Recombinant modified vaccinia virus (MVA) vaccine against coronavirus disease
AssigneeBavarian Nordic A/S
InventorsJürgen Hausmann, Robin Steigerwald, Matthias Habjan, José Medina Echeverz, Stephan Rambichler
Life of this patent
Estimating the term…
Abstract
The invention relates to a recombinant Modified Vaccinia Virus Ankara (MVA) encoding a spike (S) protein or a part thereof, such as a receptor-binding domain (RBD), and additional antigenic sequences derived from other proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease 19 (COVID-19).
Claims16
A recombinant Modified Vaccinia Virus Ankara (MVA), comprising a nucleic acid sequence encoding an amino acid sequence of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) full-length protein, wherein the amino acid sequence of the SARS-CoV-2 S full-length protein is as set forth in SEQ ID NO:
- 22 or 24.
A recombinant Modified Vaccinia Virus Ankara (MVA), comprising a nucleic acid sequence encoding an amino acid sequence of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) full-length protein, wherein the nucleic acid sequence is as set forth in SEQ ID NO:
- 23 or 25.
Dependencies are inferred from the claim text.